IL-6 Adsorption Dynamics in Hemoadsorption Beads Studied Using Confocal Laser Scanning Microscopy
Given the large diameter of our sorbent beads (450µm), less than 20% of available sorbent surface area participates in cytokine adsorption. Development of smaller beads may accelerate cytokine adsorption by maximizing available surface area per bead mass.
CytoSorb hemoadsorption beads were provided by CytoSorbents, Inc. (Monmouth Junction, NJ). CytoSorb beads are polystyrene-divinylbenzene porous particles (450µm avg. particle diameter, 67% porosity, 1.02g/cm3 density, 0.8-5nm pore diameter, 850m2/g surface area) with a biocompatible polyvinyl-pyrrolidone coating.
Given this observation, less than 20% of available sorbent surface area is utilized for cytokine adsorption. For the current large size of CytoSorb beads, the surface area for diffusion into the beads relative to bead volume is small for a given mass of beads. Smaller CytoSorb beads may provide significantly faster cytokine capture by maximizing available surface area for diffusion per bead mass. We are currently developing and testing smaller CytoSorb beads to accelerate cytokine capture in a hemoadsorption device. Enhanced removal of cytokines from the circulating blood may improve patient outcomes in severe sepsis.
Are we still using this size bead in recent trials, if not at what time and what size bead is currently used?
Is changing the bead size possible before approval? Or will they wait for approval then launch different filters with specific bead sizes?
